Peptides DB
Research-centric peptide and protocol reference hub
Study 17 of 17Tesamorelin literatureThe lancet. HIV · ReviewTop journal2015

Weight management in people with HIV.

Weight management is a pressing issue for people with HIV, with nearly half affected by obesity, highlighting the need for targeted interventions.

Read at The lancet. HIVAdd to compare

Where it sits

this study against the rest of the tesamorelin corpus
1
Preclinical
4
Observational
0
Open-label
9
Randomised
3
Reviews · this one

Summary and findings

This paper discusses weight management strategies in people with HIV, highlighting the prevalence of obesity in this population. It reviews various interventions, including behavioral changes and pharmacological therapies like GLP-1 receptor agonists and tesamorelin. The study emphasizes the need for further research on effective obesity management in individuals with HIV.

How much of this paper we could read: partial text (0.40). We had some abstract detail. Check the source for anything decisive. What this means →
Not reported in abstract.2015

Abstract

The authors’ words, as The lancet. HIV supplied them

Excess weight gain in people with HIV is now recognised as a common risk associated with the use of guideline-recommended antiretroviral therapy, such that nearly 50% of people with HIV are living with comorbid obesity. Weight gain and clinical obesity exacerbate cardiovascular-kidney-metabolic health complications in this population and chronic weight management strategies that reduce these risks are now an urgent priority. Behavioural interventions can be offered to improve diet and increase physical activity, including increasing protein intake and promoting regular physical activity. Additionally, there is a growing body of evidence to support the use of GLP-1 receptor agonist therapies in people with HIV, along with a historical literature showing the efficacy of tesamorelin; however, there are sparse data to direct the use of other approved obesity management medicines specific to this population. Finally, bariatric surgical interventions are suggested to be safe and efficacious for those with chronic HIV infection and comorbid obesity. This Series paper identifies a range of key evidence gaps and research priorities for obesity management in people with HIV, including a lack of trials of GLP-1 therapies in people with HIV powered to key clinical outcomes, such as major adverse cardiovascular events and body composition endpoints, implementation science to define models of care, and research on the heterogeneities in clinical outcomes of obesity treatment by sex.

Background

The paper addresses the clinical issue of excess weight gain in people with HIV, which is increasingly recognized as a common risk associated with antiretroviral therapy. Prior literature has shown that nearly half of individuals with HIV experience obesity, which can worsen cardiovascular, kidney, and metabolic health complications. This study is significant as it highlights the urgent need for effective weight management strategies tailored to this population.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

The findings suggest a growing recognition of obesity management in HIV care, but the lack of robust data on specific interventions limits the conclusions that can be drawn. While the paper references the efficacy of tesamorelin, it does not provide quantitative results or compare these findings to existing literature. The identified gaps in research indicate that further studies are needed to establish effective treatment protocols.

Key findings

  • Nearly 50% of people with HIV are living with comorbid obesity.
  • Chronic weight management strategies are now an urgent priority.
  • Sparse data exist to direct the use of approved obesity management medicines specific to people with HIV.

Limitations

  • Not a clinical trial, but a review of existing literature.
  • Sparse data on specific obesity management medicines for HIV patients.
  • No quantitative outcomes or effect sizes reported.

Elsewhere in the Tesamorelin corpus

BDetecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS.Drug testing and analysis · 2023 · n=6 · Limit of detection for urine was 13 pg/mL and for serum was 41 pg/mL.HumanBDetecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS.Drug testing and analysis · 2026 · Limit of detection of 13 pg/mL in urine and 41 pg/mL in serum.HumanDWeight management in people with HIV.The lancet. HIV · 2026—AEffects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.The Journal of clinical endocrinology and metabolism · 2010 · -24 +/- 41 cm(2) VAT reduction in tesamorelin vs 2 +/- 35 cm(2) in placebo at 26 wk, P < 0.001.HumanDTesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.The Annals of pharmacotherapy · 2012 · Not reported in abstract.reviewATesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.BMJ open · 2026Human